281 related articles for article (PubMed ID: 27056619)
1. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
2. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
3. Prospective Clinical Trial of
Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M
J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630
[No Abstract] [Full Text] [Related]
4. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
5. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
6. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.
Amzat R; Taleghani P; Miller DL; Beitler JJ; Bellamy LM; Nye JA; Yu W; Savir-Baruch B; Osunkoya AO; Chen Z; Auffermann WF; Goodman MM; Schuster DM
Mol Imaging Biol; 2013 Oct; 15(5):633-43. PubMed ID: 23595643
[TBL] [Abstract][Full Text] [Related]
8. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.
Buehner TM; Liotta M; Potkul RK; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2024 Feb; 26(1):45-52. PubMed ID: 36754935
[TBL] [Abstract][Full Text] [Related]
9. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
Sörensen J; Owenius R; Lax M; Johansson S
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700
[TBL] [Abstract][Full Text] [Related]
10.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of
Jambor I; Kuisma A; Kähkönen E; Kemppainen J; Merisaari H; Eskola O; Teuho J; Perez IM; Pesola M; Aronen HJ; Boström PJ; Taimen P; Minn H
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):355-364. PubMed ID: 29147764
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of fluciclovine (
Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
[TBL] [Abstract][Full Text] [Related]
13. Characterising
Scott NP; Teoh EJ; Flight H; Jones BE; Niederer J; Mustata L; MacLean GM; Roy PG; Remoundos DD; Snell C; Liu C; Gleeson FV; Harris AL; Lord SR; McGowan DR
Br J Cancer; 2022 Mar; 126(4):598-605. PubMed ID: 34795409
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [
Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [
Akintayo AA; Abiodun-Ojo OA; Weber C; Sharma J; Cohen C; Sica G; Halkar R; Goodman MM; Schuster DM
Mol Imaging Biol; 2019 Oct; 21(5):818-824. PubMed ID: 30617729
[TBL] [Abstract][Full Text] [Related]
16. Detection of Additional Primary Neoplasms on
Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
[TBL] [Abstract][Full Text] [Related]
17.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
18.
Albano D; Tomasini D; Bonù M; Giubbini R; Bertagna F
Ann Nucl Med; 2020 Feb; 34(2):81-86. PubMed ID: 31773466
[No Abstract] [Full Text] [Related]
19. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
20. Phase IIa clinical study of [
Kondo A; Ishii H; Aoki S; Suzuki M; Nagasawa H; Kubota K; Minamimoto R; Arakawa A; Tominaga M; Arai H
Ann Nucl Med; 2016 Nov; 30(9):608-618. PubMed ID: 27418267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]